InvestorsHub Logo
Followers 2
Posts 483
Boards Moderated 0
Alias Born 04/03/2017

Re: cjarmstrong post# 2646

Sunday, 07/30/2017 11:56:00 PM

Sunday, July 30, 2017 11:56:00 PM

Post# of 6315
'Plant derived drugs aren't uncommon or inferior.
The advantage with biosynthesis is mainly reduced time and cost.'

If one route of manufacturing produces a higher volume with less costs, how is the other method not inferior? I know it is not uncommon, but wouldn't cannabis variability make it more difficult than your average plant? The more variable the species = the more synthetics make the better route? Why are you even bothering Growing it considering the risks and GMP costs....

Targeted synthetics outperform the plant 10/10 times for that specific indication. Even if some of the 550ish compounds have a net positive effect, clearly it is not big enough to warrant smoking/edibles over a synthetic. And if they do have a benefit, that will be discovered and drugs improved one day.

Are cannabinoids via IV the best? The study I referenced would indicate not.....

'hough I'm skeptical that NB1111 will be successful because of tolerance'

Tolerance to what? The latest research said 1%< THC?

'"But if it's valued at a couple hundred million $$ then that's not bad for a few years work...".

Not bad at all, is that just a hypothetical figure or what you actually think it could be worth to Nemus? '

If the CINV market is 2b, and they can get 5% of that for a sustained period, you can do the math


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SKYE News